The regulatory authorities talk together a lot: FDA, EMA and Health Canada. They do coordinate. I was the author of the paper that Dr. Wright mentioned about how Canada's last within the G7 in actual approvals of these drugs.
I don't think that the primary problem is the bureaucracy within Canada. I think the primary problem is that the price is low compared to the size of Canada, so it's not an attractive enough market for the company to go to the trouble of doing that. A lot of these failures to get approvals in Canada are because no one tried, because the market's too small.
If Canada had a pull incentive at the levels I've described, I guarantee you that every company would come to Canada and the rest of the G7, with that as the carrot for them to bother with the registration.